Testimony of Dr. Aaron Kowalski, Chief Mission Officer, Breakthrough T1D House Energy & Commerce Committee Oversight And Investigations Subcommittee
‘PRICED OUT OF A LIFESAVING DRUG: THE HUMAN IMPACT OF RISING INSULIN COSTS’ Chairwoman DeGette, Ranking Member Guthrie, Chairman Pallone,…
Send a Letter to the Administration to Help Lower Insulin Prices
Earlier this year, the U.S. Department of Health and Human Services (HHS) announced a proposal to lower prescription drug prices and out-of-pocket…
Advocacy in Action: Breakthrough T1D 2019 Government Day
After nearly 500 meetings with Members of Congress, Breakthrough T1D 2019 Government Day has officially come to a close. Over…
Eli Lilly Announces Lower-Cost Generic Insulin
Eli Lilly and Company announced it will begin selling a generic version of its most commonly prescribed insulin -- Humalog
We’re the Advancing Progress Type
Breakthrough T1D Fiscal Year 2018 Annual Report As you’ll see in the pages of our fiscal year 2018 annual report,…
In a Step Backward, UnitedHealthcare Changes Policy to Limit Insulin Pumps for Children
On February 1, 2019, UnitedHealthcare (UHC) announced a significant change to its insulin pump coverage policy, as it will no…
An Important Step in the FDA Review of Sotagliflozin (Zynquista™) for T1D
You’ll hear it again and again: For some people with type 1 diabetes (T1D), SGLT inhibitor therapy* means taking less…
